Welcome to our dedicated page for POOLBEG PHARMA PLC news (Ticker: POLBF), a resource for investors and traders seeking the latest updates and insights on POOLBEG PHARMA PLC stock.
Poolbeg Pharma PLC (symbol: POLBF) is a biopharmaceutical company dedicated to developing and commercialising innovative medicines focused on diseases with significant unmet medical needs. Led by an experienced team, including the recent addition of members from Amryt Pharma plc, the company is committed to delivering value to shareholders. Poolbeg's clinical programs target large markets such as cancer immunotherapy-induced CRS, infectious diseases, and metabolic conditions like obesity, with the development of an oral GLP-1R agonist. The company utilizes a cost-effective development strategy to produce high-quality human data supporting partnerships and future development.
Rhea-AI Summary
Poolbeg Pharma (POLBF) receives a Notice of Allowance for its Immunomodulator II patent application in the United States, strengthening its intellectual property portfolio. The patent covers the potential use of POLB 001, a Phase II-ready p38 MAP kinase inhibitor, in treating hypercytokinaemia and preventing cytokine storms. This development enhances the company's value for potential pharma partners and expands its patent portfolio, particularly in cancer immunotherapies. CEO Jeremy Skillington highlights the significance of this milestone, emphasizing the potential market impact and the unmet medical need in cancer immunotherapy-induced Cytokine Release Syndrome.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Poolbeg Pharma (POLBF) CEO Jeremy Skillington purchases 154,764 ordinary shares, representing 0.17% of the company's issued share capital. The purchase was made at a price of 10.8 pence per share, indicating confidence in the company's future.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Poolbeg Pharma announces Cathal Friel's purchase of 830,000 ordinary shares at 11.68 pence per share, increasing his stake to 7.4% of the Company's issued share capital.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Poolbeg Pharma announces a change in Board role and approval of an Employee Performance Incentive Plan. Cathal Friel becomes Executive Chairman, and an EIP is adopted to align objectives with shareholders. The plan awards long-term incentive options to key senior management. The company focuses on rare diseases and profitable revenues, with a strong management team in place for growth and value creation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Poolbeg Pharma announces a >$10 billion market opportunity for POLB 001 in Cancer Immunotherapy-Induced CRS, supported by independent research. The company aims to focus on Rare and Orphan Diseases, leveraging the expertise of the former Amryt team. POLB 001 shows promise in addressing CRS induced by CAR-T and BsAb treatments, with potential cost-saving benefits and improved patient access to therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Poolbeg Pharma announces promising in vivo results for POLB 001 in addressing cancer immunotherapy-induced CRS. POLB 001 demonstrated efficacy in reducing CRS symptoms in an animal model, with potential market opportunity estimated at over US$1 billion. Independent Advisory Board supports POLB 001's potential as an oral therapy to address unmet medical need.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF) announces positive lab-based analysis and successful prioritization of RSV drug candidates, reflecting the high potential of its AI-led program.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF) presented key insights at the 65th American Society of Hematology Annual Meeting and Exposition regarding their potential therapy, POLB 001, for Cytokine Release Syndrome (CRS) associated with cancer immunotherapies. The poster detailed positive results from the LPS human challenge trial, demonstrating good safety and tolerability, a clear dose-response relationship, and a reduction in pro-inflammatory cytokines. Phase II trial enabling activities are underway with strong interest from potential pharma partners.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Poolbeg Pharma (POLB) announces the resignation of Patrick Ashe, Independent Non-Executive Director, and the appointment of Eddie Gibson as Chair of the Audit & Risk Committee and Prof Brendan Buckley as Chair of the Remuneration Committee. The company is on an upward trajectory with a robust pipeline of high-value programs and aims to replicate the success of former Amryt Pharma plc leadership members recently appointed to the Poolbeg team. With strong financials, excellent clinical results, and productive partnering discussions, Poolbeg is well-positioned to generate significant shareholder value.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Poolbeg Pharma (POLB) has received official decision from the Japanese Patent Office to grant Poolbeg's Immunomodulator II patent application, further strengthening the Company's robust intellectual property in the territory. Additionally, the fully granted patent for Immunomodulator I has been received from the Japanese Patent Office. Poolbeg has a worldwide license for POLB 001 for all uses in humans and is developing a strong IP portfolio with patents in place, covering the use of p38 MAP kinase inhibitors for the treatment of severe influenza and hypercytokinemia, as well as alongside cancer immunotherapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
FAQ
What is the current stock price of POOLBEG PHARMA PLC (POLBF)?
The current stock price of POOLBEG PHARMA PLC (POLBF) is $0.151 as of February 7, 2025.
What is the market cap of POOLBEG PHARMA PLC (POLBF)?
The market cap of POOLBEG PHARMA PLC (POLBF) is approximately 59.0M.
What is Poolbeg Pharma PLC focused on?
Poolbeg Pharma PLC focuses on developing and commercialising innovative medicines targeting diseases with a high unmet medical need.
Who leads Poolbeg Pharma PLC?
Poolbeg Pharma PLC is led by an experienced leadership team, including former members of Amryt Pharma plc.
What are the key areas of focus for Poolbeg's clinical programs?
Poolbeg's clinical programs target large addressable markets including cancer immunotherapy-induced CRS, infectious disease, and metabolic conditions like obesity.
What is Poolbeg's development strategy?
Poolbeg uses a cost-effective development philosophy to generate high-quality human data supporting partnering and further development.
What recent announcement has Poolbeg Pharma PLC made?
Poolbeg Pharma PLC has received notification of the Executive Chairman's purchase of ordinary shares, strengthening the company's position.
What intellectual property advancements has Poolbeg made?
Poolbeg Pharma PLC has recently been granted a significant patent related to its Immunomodulator II, further strengthening its robust intellectual property portfolio.
What strategic agreement has Poolbeg entered into?
Poolbeg Pharma PLC has entered into an exclusive option agreement to acquire an orphan drug candidate for Behçet's Disease.
What is the focus of Poolbeg's option agreement?
The exclusive option agreement is for a novel topical muco-adherent formulation of Pentoxifylline (tPTX) for the treatment of oral ulcers in patients with Behçet's Disease.
What market opportunity does Poolbeg target?
Poolbeg Pharma PLC aims to address market opportunities exceeding US$10 billion, particularly in cancer immunotherapy-induced CRS.
What recent patent grant has Poolbeg received?
Poolbeg Pharma PLC has received a fully granted patent from the US Patent Office for its Immunomodulator II patent application.
POOLBEG PHARMA PLC